Extension Study of Secukinumab Prefilled Syringes in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis Completing Preceding Secukinumab Phase III Studies
Phase 3
- Conditions
- psoriasis
- Registration Number
- JPRN-jRCT2080221919
- Lead Sponsor
- ovartis Pharma K.K.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Subjects who complete the full study treatment period of preceding phase III studies.
-Subjects expected to benefit from participation in the extension study, as assessed by the subject and investigator
Ages Eligible for Study: 18 Years and older
Genders Eligible for Study: Both
Exclusion Criteria
-Ongoing use of prohibited psoriasis or non-psoriasis treatments.
-Other protocol-defined inclusion/exclusion criteria may apply.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method AE
- Secondary Outcome Measures
Name Time Method PASI 75, IGA